Literature DB >> 16393224

Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.

Claudio Zavaglia1, Luciano De Carlis, Alberto Battista Alberti, Ernesto Minola, Luca Saverio Belli, Abdallah Omar Slim, Aldo Airoldi, Alessandro Giacomoni, Gianfranco Rondinara, Carmine Tinelli, Domenico Forti, Giovambattista Pinzello.   

Abstract

AIMS: The aim of this study was to identify predictors of both survival and tumor-free survival of a cohort of 155 patients, with hepatocellular carcinoma (HCC) and cirrhosis, who were treated by orthotopic liver transplantation (OLT).
METHODS: From January 1989 to December 2002, 603 OLTs were performed in 549 patients. HCC was diagnosed in 116 patients before OLT and in 39 at histological examination of the explanted livers. Eighty-four percent of the patients met "Milan" criteria at histology. Ninety-four patients received anticancer therapies preoperatively.
RESULTS: The median follow-up was 49 months (range, 0-178). Overall, 1-, 3-, 5-, and 10-yr survival were 84%, 75%, 72%, and 62%, respectively. Survival was not affected by the patient's age or sex, etiology of liver disease, Child score at transplantation, rejection episodes, tumor number, total tumor burden, bilobar tumor, and pathologic Tumor, Nodes, Metastasis (pTNM) stages. There was no statistically significant difference in survival when patients were grouped according to the recently proposed simplified pTNM staging (5-yr survival, 80% in stage I, 69% in stage II, 50% in stage III, p= 0.3) or the United Network for Organ Sharing (UNOS) staging system for HCC. Encapsulation of the tumor and alpha-fetoprotein levels significantly affect patient survival. Five-year survival of patients with poorly differentiated (G3) HCC was significantly worse than that of patients with moderately (G2) or well-differentiated (G1) HCC (respectively, G3 44%, G2 67%, and G1 97%, p= 0.0015). Patients with micro- or macro-vascular invasion had a worse 5-yr survival than patients without vascular invasion (49%vs 77%, p= 0.04). Multivariate analysis showed that histological grade of differentiation and macroscopic vascular invasion are independent predictors of survival (HR 2.4, 95% CI 1.4-4.1, p= 0.0009 and HR 2.8, 95% CI 1.2-6.8, p= 0.022).
CONCLUSION: Histological grade of differentiation and macroscopic vascular invasion, as assessed on the explanted livers, are strong predictors of both survival and tumor recurrence in patients with cirrhosis who received transplants for HCC.

Entities:  

Mesh:

Year:  2005        PMID: 16393224     DOI: 10.1111/j.1572-0241.2005.00289.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  49 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

2.  Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria.

Authors:  Takanori Sakaguchi; Shohachi Suzuki; Yoshifumi Morita; Kousuke Oishi; Atsushi Suzuki; Kazuhiko Fukumoto; Keisuke Inaba; Satoshi Nakamura; Hiroyuki Konno
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

3.  Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.

Authors:  Steven-Huy Han; K Rajender Reddy; Emmet B Keeffe; Consuelo Soldevila-Pico; Robert Gish; Raymond T Chung; Bulent Degertekin; Anna Lok
Journal:  Clin Transplant       Date:  2010-11-16       Impact factor: 2.863

4.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

5.  "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

6.  Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection.

Authors:  Li Zhou; Jing-An Rui; Da-Xiong Ye; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

7.  Liver transplantation for hepatocellular carcinoma: how far can the selection criteria be expanded?

Authors:  Naglaa Allam
Journal:  Hepatol Int       Date:  2012-02-10       Impact factor: 6.047

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Xiao Xu; Qing-Hong Ke; Zhe-Xin Shao; Jian Wu; Jun Chen; Lin Zhou; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2008-06-18       Impact factor: 3.199

10.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.